Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations
JCO Oncology Practice · 2024-02 · 20 (2) · 278-290
DOI: 10.1200/op.23.00495 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2024-02. Verfasst von Mary Linton B Peters und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA. Hauptthemen laut MEDLINE: Cost-Effectiveness Analysis, Pancreatic Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE We evaluated the potential cost-effectiveness of combined magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) screening for pancreatic ductal adenocarcinoma (PDAC) among populations at high risk for the disease. METHODS We used a microsimulation model of the natural history of PDAC to estimate the lifetime health benefits, costs, and cost-effectiveness of PDAC screening among populations with specific genetic risk factors for PDAC, including BRCA1 and BRCA2, PALB2, ATM, Lynch syndrome, TP53, CDKN2A, and STK11. For each high-risk population, we simulated 29 screening strategies, defined by starting age and frequency. Screening included MRI with follow-up EUS in a subset of patients. Costs of tests were based on Medicare reimbursement for MRI, EUS, fine-needle aspiration biopsy, and pancreatectomy. Cancer-related cost by stage of disease and phase of treatment was based on the literature. For each high-risk population, we performed an incremental cost-effectiveness analysis, assuming a willingness-to-pay (WTP) threshold of $100,000 US dollars (USD) per quality-adjusted life year (QALY) gained. RESULTS For men with relative risk (RR) 12.33 ( CDKN2A) and RR 28 ( STK11), annual screening was cost-effective, starting at age 55 and 40 years, respectively. For women, screening was only cost-effective for those with RR 28 ( STK11), with annual screening starting at age 45 years. CONCLUSION Combined MRI/EUS screening may be a cost-effective approach for the highest-risk populations (among mutations considered, those with RR >12). However, for those with moderate risk (RR, 5-12), screening would only be cost-effective at higher WTP thresholds (eg, $200K USD/QALY) or with once-only screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA.
- Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA.
- Department of Radiology, The Ohio State University College of Medicine, Columbus, OH.
- Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA.
- Department of Radiology, Massachusetts General Hospital, Boston, MA.
ORCID-Profile: Mary Linton B Peters, Andrew Eckel, Claudia L Seguin, David H Howard, Amy B Knudsen
Förderung
- NCI NIH HHS
Zitieren
APA
Peters, M. L. B., Eckel, A., Seguin, C. L., Davidi, B., Howard, D. H., Knudsen, A. B., & Pandharipande, P. V. (2024). Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations. JCO Oncology Practice, 20(2), 278-290. https://doi.org/10.1200/op.23.00495
Vancouver
Peters MLB, Eckel A, Seguin CL, Davidi B, Howard DH, Knudsen AB, et al. Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations. JCO Oncology Practice. 2024;20(2):278-290. doi:10.1200/op.23.00495
BibTeX
@article{Peters2024,
author = {Peters, Mary Linton B and Eckel, Andrew and Seguin, Claudia L and Davidi, Barak and Howard, David H and Knudsen, Amy B and Pandharipande, Pari V},
title = {Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations},
journal = {JCO Oncology Practice},
year = {2024},
volume = {20},
number = {2},
pages = {278--290},
doi = {10.1200/op.23.00495}
}
EUVIMED